Interpace Biosciences Inc (IDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Sales | 10,106 | 9,078 | 11,026 | 9,826 | 8,331 |
| Cost of Goods | 2,817 | 4,124 | 4,191 | 3,848 | 3,320 |
| Gross Profit | 7,289 | 4,954 | 6,835 | 5,978 | 5,011 |
| Operating Expenses | 5,641 | 5,094 | 6,194 | 6,151 | 5,277 |
| Operating Income | 2,465 | -16 | 832 | 675 | 54 |
| Interest Expense | 77 | 0 | 0 | 35 | 0 |
| Other Income | -416 | -508 | -433 | -206 | -1,457 |
| Pre-tax Income | 1,972 | -524 | 399 | 434 | -1,403 |
| Income Tax | 5 | 4 | 4 | 4 | 6 |
| Net Income Continuous | 1,967 | -528 | 395 | 430 | -1,409 |
| Net Income Discontinuous | 75 | -86 | -220 | -79 | -155 |
| Net Income | $2,042 | $-614 | $175 | $351 | $-1,564 |
| EPS Basic Total Ops | 0.47 | -0.14 | 0.04 | 0.08 | -0.37 |
| EPS Basic Continuous Ops | 0.45 | -0.12 | 0.09 | 0.10 | -0.32 |
| EPS Basic Discontinuous Ops | 0.02 | -0.02 | -0.05 | -0.02 | -0.05 |
| EPS Diluted Total Ops | 0.47 | -0.14 | 0.04 | 0.08 | -0.37 |
| EPS Diluted Continuous Ops | 0.45 | -0.12 | 0.09 | 0.10 | -0.32 |
| EPS Diluted Discontinuous Ops | 0.02 | -0.02 | -0.05 | -0.02 | -0.05 |
| EBITDA(a) | $2,651 | $350 | $1,412 | $1,186 | $1,365 |